SAB Biotherapeutics (SABS) Competitors $2.10 -0.02 (-0.94%) Closing price 08/28/2025 03:59 PM EasternExtended Trading$2.08 -0.02 (-0.71%) As of 08:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SABS vs. FBIO, CRIS, BOLT, AMGN, GILD, VRTX, REGN, ALNY, BIIB, and INCYShould you be buying SAB Biotherapeutics stock or one of its competitors? The main competitors of SAB Biotherapeutics include Fortress Biotech (FBIO), Curis (CRIS), Bolt Biotherapeutics (BOLT), Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), and Incyte (INCY). These companies are all part of the "biotechnology" industry. SAB Biotherapeutics vs. Its Competitors Fortress Biotech Curis Bolt Biotherapeutics Amgen Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen Incyte Fortress Biotech (NASDAQ:FBIO) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends. Which has better valuation & earnings, FBIO or SABS? SAB Biotherapeutics has lower revenue, but higher earnings than Fortress Biotech. Fortress Biotech is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFortress Biotech$57.67M1.25-$46M-$1.05-2.30SAB Biotherapeutics$1.32M16.56-$34.10M-$4.00-0.53 Do analysts recommend FBIO or SABS? Fortress Biotech currently has a consensus target price of $16.50, suggesting a potential upside of 581.82%. SAB Biotherapeutics has a consensus target price of $11.00, suggesting a potential upside of 423.81%. Given Fortress Biotech's higher possible upside, equities analysts plainly believe Fortress Biotech is more favorable than SAB Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fortress Biotech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00SAB Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, FBIO or SABS? Fortress Biotech has a beta of 1.76, indicating that its stock price is 76% more volatile than the S&P 500. Comparatively, SAB Biotherapeutics has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Do insiders & institutionals have more ownership in FBIO or SABS? 96.5% of Fortress Biotech shares are held by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are held by institutional investors. 27.9% of Fortress Biotech shares are held by insiders. Comparatively, 27.8% of SAB Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media refer more to FBIO or SABS? In the previous week, Fortress Biotech had 10 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 11 mentions for Fortress Biotech and 1 mentions for SAB Biotherapeutics. SAB Biotherapeutics' average media sentiment score of 1.88 beat Fortress Biotech's score of 0.59 indicating that SAB Biotherapeutics is being referred to more favorably in the news media. Company Overall Sentiment Fortress Biotech Positive SAB Biotherapeutics Very Positive Is FBIO or SABS more profitable? SAB Biotherapeutics has a net margin of 0.00% compared to Fortress Biotech's net margin of -24.84%. SAB Biotherapeutics' return on equity of -153.92% beat Fortress Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Fortress Biotech-24.84% -301.81% -27.48% SAB Biotherapeutics N/A -153.92%-89.16% SummaryFortress Biotech beats SAB Biotherapeutics on 8 of the 15 factors compared between the two stocks. Get SAB Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SABS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SABS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SABS vs. The Competition Export to ExcelMetricSAB BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.07M$3.10B$5.78B$9.79BDividend YieldN/A2.26%3.95%4.02%P/E Ratio-0.5321.0831.2626.59Price / Sales16.56356.05436.91155.84Price / CashN/A44.6737.7359.36Price / Book1.838.0910.736.68Net Income-$34.10M-$54.08M$3.27B$265.59M7 Day Performance-2.78%-0.41%1.42%0.62%1 Month Performance-7.49%6.23%6.21%2.61%1 Year Performance-28.57%10.45%51.81%22.34% SAB Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SABSSAB Biotherapeutics2.6623 of 5 stars$2.10-0.9%$11.00+423.8%-28.3%$22.07M$1.32M-0.53140FBIOFortress Biotech2.8208 of 5 stars$2.25flat$21.00+833.3%+18.6%$66.68M$57.78M-2.15170Gap UpCRISCuris3.0578 of 5 stars$1.75+1.2%$17.00+871.4%-70.9%$21.54M$10.91M-0.3560Gap UpBOLTBolt Biotherapeutics3.2642 of 5 stars$5.12+1.0%$47.50+827.6%-61.6%$9.82M$4.17M-0.1990Positive NewsGap DownAMGNAmgen4.6992 of 5 stars$294.66+0.7%$303.76+3.1%-13.3%$158.46B$34.92B24.0728,000Trending NewsAnalyst RevisionGILDGilead Sciences4.977 of 5 stars$118.29+0.3%$115.39-2.5%+43.3%$146.66B$28.86B23.5517,600Positive NewsVRTXVertex Pharmaceuticals4.945 of 5 stars$391.26+0.4%$497.10+27.1%-19.9%$100.43B$11.02B28.006,100Positive NewsREGNRegeneron Pharmaceuticals4.8595 of 5 stars$581.56+1.3%$829.65+42.7%-51.7%$61.30B$14.20B14.5815,106Trending NewsAnalyst ForecastALNYAlnylam Pharmaceuticals4.1711 of 5 stars$456.91+1.8%$405.33-11.3%+61.1%$60.08B$2.46B-185.572,230Positive NewsBIIBBiogen4.8194 of 5 stars$137.93+1.5%$185.74+34.7%-35.0%$20.22B$10.00B13.197,605Positive NewsINCYIncyte4.6691 of 5 stars$85.25+0.4%$81.20-4.7%+27.5%$16.66B$4.24B19.392,617 Related Companies and Tools Related Companies FBIO Competitors CRIS Competitors BOLT Competitors AMGN Competitors GILD Competitors VRTX Competitors REGN Competitors ALNY Competitors BIIB Competitors INCY Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SABS) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SAB Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SAB Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access